CoChat

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization

Open access

Abstract

Exendin-4 is a glucagon-like receptor 1 agonist clinically used against type 2 diabetes that has also shown neuroprotective effects in experimental stroke models. However, while the neuroprotective efficacy of Exendin-4 has been thoroughly investigated if the pharmacological treatment starts before stroke, the therapeutic potential of the Exendin-4 if the treatment starts acutely after stroke has not been clearly determined. Further, a comparison of the neuroprotective efficacy in normal and aged diabetic mice has not been performed. Finally, the cellular mechanisms behind the efficacy of Exendin-4 have been only partially studied. The main objective of this study was to determine the neuroprotective efficacy of Exendin-4 in normal and aged type 2 diabetic mice if the treatment started after stroke in a clinically relevant setting. Furthermore we characterized the Exendin-4 effects on stroke-induced neuroinflammation. Two-month-old healthy and 14-month-old type 2 diabetic/obese mice were subjected to middle cerebral artery occlusion. 5 or 50 µg/kg Exendin-4 was administered intraperitoneally at 1.5, 3 or 4.5 hours thereafter. The treatment was continued (0.2 µg/kg/day) for 1 week. The neuroprotective efficacy was assessed by stroke volume measurement and stereological counting of NeuN-positive neurons. Neuroinflammation was determined by gene expression analysis of M1/M2 microglia subtypes and pro-inflammatory cytokines. We show neuroprotective efficacy of 50 µg/kg Exendin-4 at 1.5 and 3 hours after stroke in both young healthy and aged diabetic/obese mice. The 5 µg/kg dose was neuroprotective at 1.5 hour only. Proinflammatory markers and M1 phenotype were not impacted by Exendin-4 treatment while M2 markers were significantly up regulated. Our results support the use of Exendin-4 to reduce stroke-damage in the prehospital/early hospitalization setting irrespectively of age/diabetes. The results indicate the polarization of microglia/macrophages towards the M2 reparative phenotype as a potential mechanism of neuroprotection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0103114

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Stroke damage analyses. A. Representative photomicrographs of brain sections (NeuN immunostained) used in quantitative analyses. B. Representative image of stroke-damaged brain. Solid black line denotes the area of the infarct size/stroke volume measurement. Solid white line denotes the area of decreased neuronal density after MCAO. Dashed black line denotes the area of neuronal quantification by stereology methods.
Figure 1 Stroke damage analyses. A. Representative photomicrographs of brain sections (NeuN immunostained) used in quantitative analyses. B. Representative image of stroke-damaged brain. Solid black line denotes the area of the infarct size/stroke volume measurement. Solid white line denotes the area of decreased neuronal density after MCAO. Dashed black line denotes the area of neuronal quantification by stereology methods.CC BY · PubMed Central
Figure 2 Neuroprotective effects of Ex-4 in normal, adult mice (Studies 1–2). Stroke volume at one week after 5 µg/kg or 50 µg/kg of Ex-4 administration (A). Number of surviving neurons in striatum (B) and cortex (C) at one week after 5 µg/kg or 50 µg/kg Ex-4 administration at 1.5, 3 and 4.5 hours after MCAO. The dashed lines on B, C indicate the number of neurons in the contralateral, corresponding intact brain areas. Data are presented as means ± SEM. *, ** and *** denote p<0.05, p<0.01 and p<0.001 respectively.
Figure 2 Neuroprotective effects of Ex-4 in normal, adult mice (Studies 1–2). Stroke volume at one week after 5 µg/kg or 50 µg/kg of Ex-4 administration (A). Number of surviving neurons in striatum (B) and cortex (C) at one week after 5 µg/kg or 50 µg/kg Ex-4 administration at 1.5, 3 and 4.5 hours after MCAO. The dashed lines on B, C indicate the number of neurons in the contralateral, corresponding intact brain areas. Data are presented as means ± SEM. *, ** and *** denote p<0.05, p<0.01 and p<0.001 respectively.CC BY · PubMed Central
Figure 3 Neuroprotective effects of Ex-4 in aged, diabetic/obese mice (Study 3). Stroke volume at one week after 50 µg/kg (A) Ex-4 administration. Number of surviving neurons in the striatum (B) and cortex (C) at one week after 50 µg/kg Ex-4 administration at 1.5 and 3 hours after MCAO. The dashed lines on B and C indicate the number of neurons in the contralateral corresponding intact brain areas. Data are presented as means ± SEM. * denotes p<0.05.
Figure 3 Neuroprotective effects of Ex-4 in aged, diabetic/obese mice (Study 3). Stroke volume at one week after 50 µg/kg (A) Ex-4 administration. Number of surviving neurons in the striatum (B) and cortex (C) at one week after 50 µg/kg Ex-4 administration at 1.5 and 3 hours after MCAO. The dashed lines on B and C indicate the number of neurons in the contralateral corresponding intact brain areas. Data are presented as means ± SEM. * denotes p<0.05.CC BY · PubMed Central
Figure 4 Stroke increase gene expression of pro-inflammatory cytokines (Study 4). Gene expression of pro-inflammatory cytokines MCP-1 (A), IL-1β (B) and TNFα (C) was analyzed by real-time PCR in brain homogenate from mice 3 days after MCAO. Gene expression was normalized to YWHAZ and expressed as arbitrary units (AU). Data are presented as means ± SEM. ** and *** denote p<0.01 and p<0.001 respectively.
Figure 4 Stroke increase gene expression of pro-inflammatory cytokines (Study 4). Gene expression of pro-inflammatory cytokines MCP-1 (A), IL-1β (B) and TNFα (C) was analyzed by real-time PCR in brain homogenate from mice 3 days after MCAO. Gene expression was normalized to YWHAZ and expressed as arbitrary units (AU). Data are presented as means ± SEM. ** and *** denote p<0.01 and p<0.001 respectively.CC BY · PubMed Central
Figure 5 Ex-4 treatment polarizes microglia towards a reparative M2 phenotype (Study 4). Microglial phenotype was determined by real-time PCR analysis of M1 markers CD86 and, iNOS (A), and M2 markers CD206, Arginase1 (Arg1) and YM1/2 (B) 3 days after MCAO. Gene expression was normalized to YWHAZ and expressed as arbitrary units (AU). Data are presented as means ± SEM. *, ** and *** denote p<0.05, p<0.01 and p<0.001 respectively.
Figure 5 Ex-4 treatment polarizes microglia towards a reparative M2 phenotype (Study 4). Microglial phenotype was determined by real-time PCR analysis of M1 markers CD86 and, iNOS (A), and M2 markers CD206, Arginase1 (Arg1) and YM1/2 (B) 3 days after MCAO. Gene expression was normalized to YWHAZ and expressed as arbitrary units (AU). Data are presented as means ± SEM. *, ** and *** denote p<0.05, p<0.01 and p<0.001 respectively.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 92

Metadata

Authors
Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C.
Affiliations
  • Karolinska Institutet (SE)
  • University of Gothenburg (SE)
  • Södertälje Sjukhus (SE)
Corresponding author
  • Darsalia, Vladimer
  • Patrone, Cesare
Venue
PLoS ONE
Published
2014-08-07
Volume
9
Issue
8
Pages
e103114
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2009256046
Cited by
92
References
41
Citations by year
2026: 3 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 11 · 2020: 7 · 2019: 16 · 2018: 8 · 2017: 12 · 2016: 5 · 2015: 8
FWCI
4.33
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Eli Lilly and Company
  • Diabetes Research and Wellness Foundation
  • European Foundation for the Study of Diabetes
  • AFA Försäkring
  • Novo Nordisk
  • Vetenskapsrådet
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
  • Svenska Läkaresällskapet
  • Diabetesfonden (DIA2013-010)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords
exendin-4, type 2 diabetes, ischemic stroke, neuroprotection, microglial M2 polarization, neuroinflammation, middle cerebral artery occlusion, GLP-1 receptor agonists, inflammatory cytokines, M1/M2 microglia
MeSH terms
Exenatide, Animals, Brain Ischemia, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, Male, Mice, Inbred C57BL, Peptides, Phenotype, Time Factors, Venoms, Biomarkers, Microglia, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Stroke, Gene Expression Profiling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization. https://app.cochat.ai/papers/10.1371/journal.pone.0103114
The paper
Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014). Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization. PLoS ONE. https://doi.org/10.1371/journal.pone.0103114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.